# General Permission

Dear Mr/Ms <<fill in>>

I kindly ask for the permission to perform the *World Delirium Awareness Day (WDAD) 1-day point delirium prevalence study* at the <<name of hospital>> on following wards/units:

* <<ward name 1>>
* <<ward name 2>>
* <<ward name 3>>

The *WDAD 1-day point delirium prevalence study* is a worldwide study on the next World Delirium Awareness Day on March 15th 2023. It is an observational prevalence study. The primary outcome is the rate of delirium at 8 a.m. in the morning and 8 p.m. in the evening, assessed by retrospective chart review by leading physicians and nurses of the ward/unit.

The special feature is that no patient data will be collected. For assessing the primary outcome, four questions will be asked:

1. Total patients: How many patients were present on the ward/unit in the morning at 8 a.m.?
2. Assessed patients: How many patients were assessed for delirium by using the reported assessment?
3. Delirious patients: How many patients were assessed positive for delirium by using the reported assessment?
4. Not assessable patients: How many patients were not assessable for delirium (e.g. comatose, sedated, away for procedures, aphasic, different language, or else)?

The answers will be e.g. “10”, “8”, “4”, “2”. No patient data will be collected.

Secondary outcome parameters are ward/unit specific delirium-specific items:

* Structures (such as present protocols, information flyer, others),
* Processes (such as frequent delirium assessment, type of delirium assessment, others),
* Barriers (such as lack of staff, missing knowledge, others), and
* Priorities in the future

All data will be collected in an online survey, using Survey Monkey.

The study is led by an international research team Dr. Heidi Lindroth (USA), Dr. Keibun Liu (Australia), and Dr. Rebecca von Haken and Dr. Peter Nydahl (Germany). In this country, the study is coordinated by

* <<name of national collaborator 1>>
* <<name of national collaborator 2>>

The study is registered in the German Registry of Clinical Trials (DRKS00030002), in concordance with the European Law of Data Protection, and has an ethic approval

* Ethic Committee of Christian-Albrechts-University Kiel, Germany (D 519/22)
* Ethic Committee of University Hospital Mannheim, Germany (D 2022-617)
* And in several other countries (see website).

The studies’ website is [www.wdad-study.center](http://www.wdad-study.center), where further information is provided.

The results will be published in peer-reviewed journals. Sub analysis for this country and hospital will be feasible and enable a benchmarking of our quality of delirium care. The results will identify opportunities for improvement and future directions of care and research.

Attached is the official study proposal, the data collecting form, and ethic approvals.

I would be pleased if you support this study. In case you have any further questions, I am at your disposal.

Yours’s sincerely

<<sign>>